Expand / Collapse search
Watch TV
☰

Quotes displayed in real-time or delayed by at least 15 minutes. Market data provided by Factset. Powered and implemented by FactSet Digital Solutions.  Legal Statement.

This material may not be published, broadcast, rewritten, or redistributed. ©2026 FOX News Network, LLC. All rights reserved. FAQ - New Privacy Policy

ingevity corp. - NGVT

NGVT

Close Chg Chg %
72.30 -1.20 -1.66%

Closed Market

71.10

-1.20 (1.66%)

Volume: 250.15K

Last Updated:

Apr 2, 2026, 3:59 PM EDT

Trade Now

Company Overview: ingevity corp. - NGVT

NGVT Key Data

Open

$70.92

 Day Range

70.37 - 72.51

52 Week Range

28.50 - 76.95

 Market Cap

$2.51B

Shares Outstanding

35.29M

 Public Float

34.76M

Beta

1.27

 Rev. Per Employee

N/A

P/E Ratio

N/A

 EPS

-$4.65

Yield

0.00%

 Dividend

N/A

EX-DIVIDEND DATE

SHORT INTEREST

N/A

AVERAGE VOLUME

387.67K

  

NGVT Performance

1 Week
 
 0.74%
 
1 Month
 
 9.45%
 
3 Months
 
 18.31%
 
1 Year
 
 126.19%
 
5 Years
 
 -6.13%
 

NGVT Analyst Ratings

  • Sell
  • Under
  • Hold
  • Over
  • Buy
Number of Ratings 4
Full Ratings ➔

About ingevity corp. - NGVT

Ingevity Corp. engages in the manufacture of specialty chemicals and carbon materials. It operates through the following segments: Performance Chemicals, Performance Materials and Advanced Polymer Technologies. The Performance Materials segment consists of automotive technologies and process purifications product families. Automotive technologies produce automotive carbon products used in gasoline vapor emission control systems in cars, trucks, motorcycles and boats. Process purifications produce a number of activated carbon products for food, water, beverage and chemical purification applications. The Performance Chemicals segment primarily addresses applications in three product families: pavement technologies, oilfield technologies, and industrial specialties. The Advanced Polymer Technologies segment produces caprolactone and caprolactone-based polymers for use in coatings, resins, elastomers, adhesives, bioplastics, and medical devices. The company was founded on March 27, 2015 and is headquartered in North Charleston, SC.

NGVT At a Glance

Ingevity Corp.
4920 O'Hear Avenue
North Charleston, South Carolina 29405
Phone 1-843-740-2300 Revenue 1.17B
Industry Chemicals: Major Diversified Net Income -167,100,000.00
Sector Process Industries Employees 1,500
Fiscal Year-end 12 / 2026
View SEC Filings

NGVT Valuation

P/E Current N/A
P/E Ratio (with extraordinary items) N/A
P/E Ratio (without extraordinary items) N/A
Price to Sales Ratio 1.835
Price to Book Ratio 70.709
Price to Cash Flow Ratio 6.47
Enterprise Value to EBITDA 8.996
Enterprise Value to Sales 2.832
Total Debt to Enterprise Value 0.376

NGVT Efficiency

Revenue/Employee 778,600.00
Income Per Employee -111,400.00
Receivables Turnover 7.401
Total Asset Turnover 0.636

NGVT Liquidity

Current Ratio 1.331
Quick Ratio 0.783
Cash Ratio 0.23

NGVT Profitability

Gross Margin 36.947
Operating Margin 22.476
Pretax Margin -12.167
Net Margin -14.308
Return on Assets -8.182
Return on Equity -133.659
Return on Total Capital -11.812
Return on Invested Capital -10.793

NGVT Capital Structure

Total Debt to Total Equity 4,184.175
Total Debt to Total Capital 97.666
Total Debt to Total Assets 75.265
Long-Term Debt to Equity 3,985.859
Long-Term Debt to Total Capital 93.037
  • Income Statement
  • Balance Sheet
  • Cash Flow Statement

Annual Financials for Ingevity Corp. - NGVT

Collapse All in section
All values USD millions. 2022 2023 2024 2025 5-year trend
Sales/Revenue
1.67B 1.69B 1.41B 1.17B
Sales Growth
+19.72% +1.59% -16.92% -16.95%
Cost of Goods Sold (COGS) incl D&A
1.13B 1.27B 975.10M 736.40M
COGS excluding D&A
- - - -
-
Depreciation & Amortization Expense
124.90M 141.40M 108.30M 105.20M
Depreciation
91.30M 62.10M 76.10M 74.60M
Amortization of Intangibles
33.60M 79.30M 32.20M 30.60M
COGS Growth
+23.50% +12.44% -22.94% -24.48%
Gross Income
541.00M 427.50M 431.20M 431.50M
Gross Income Growth
+12.57% -20.98% +0.87% +0.07%
Gross Profit Margin
+32.47% +25.25% +30.66% +36.95%
2022 2023 2024 2025 5-year trend
SG&A Expense
195.50M 173.60M 162.60M 169.00M
Research & Development
30.30M 31.80M 28.10M 28.40M
Other SG&A
165.20M 141.80M 134.50M 140.60M
SGA Growth
+13.40% -11.20% -6.34% +3.94%
Other Operating Expense
- - - 6.30M
-
Unusual Expense
17.70M 173.80M 640.40M 305.10M
EBIT after Unusual Expense
327.80M 80.10M (378.10M) (42.60M)
Non Operating Income/Expense
3.60M 3.10M (59.70M) (21.20M)
Non-Operating Interest Income
6.40M 6.30M 7.70M 4.40M
Equity in Earnings of Affiliates
- - - -
-
Interest Expense
61.80M 93.30M 97.80M 78.30M
Interest Expense Growth
+19.54% +50.97% +4.82% -19.94%
Gross Interest Expense
61.80M 93.30M 97.80M 78.30M
Interest Capitalized
- - - -
-
Pretax Income
269.60M (10.10M) (535.60M) (142.10M)
Pretax Income Growth
+65.60% -103.75% -5,202.97% +73.47%
Pretax Margin
+16.18% -0.60% -38.09% -12.17%
Income Tax
58.00M (4.70M) (105.30M) 8.20M
Income Tax - Current - Domestic
48.00M 28.70M 1.80M 2.90M
Income Tax - Current - Foreign
15.00M 11.30M 14.30M 10.20M
Income Tax - Deferred - Domestic
(6.30M) (44.30M) (117.80M) (500.00K)
Income Tax - Deferred - Foreign
1.30M (400.00K) (3.60M) (4.40M)
Income Tax Credits
- - - -
-
Equity in Earnings of Affiliates
- - - -
-
Other After Tax Income (Expense)
- - - -
-
Consolidated Net Income
211.60M (5.40M) (430.30M) (150.30M)
Minority Interest Expense
- - - -
-
Net Income
211.60M (5.40M) (430.30M) (150.30M)
Net Income Growth
+79.17% -102.55% -7,868.52% +65.07%
Net Margin Growth
+12.70% -0.32% -30.60% -12.87%
Extraordinaries & Discontinued Operations
- - - (16.80M)
-
Discontinued Operations
- - - (16.80M)
-
Net Income After Extraordinaries
211.60M (5.40M) (430.30M) (167.10M)
Preferred Dividends
- - - -
-
Net Income Available to Common
211.60M (5.40M) (430.30M) (167.10M)
EPS (Basic)
5.5423 -0.148 -11.8465 -4.6132
EPS (Basic) Growth
+86.85% -102.67% -7,904.39% +61.06%
Basic Shares Outstanding
38.18M 36.50M 36.32M 36.22M
EPS (Diluted)
5.5002 -0.148 -11.8465 -4.6132
EPS (Diluted) Growth
+86.56% -102.69% -7,904.39% +61.06%
Diluted Shares Outstanding
38.47M 36.50M 36.32M 36.22M
EBITDA
470.40M 395.30M 370.60M 367.70M
EBITDA Growth
+8.04% -15.97% -6.25% -0.78%
EBITDA Margin
+28.23% +23.35% +26.35% +31.48%

Snapshot

Average Recommendation OVERWEIGHT Average Target Price 76.00
Number of Ratings 4 Current Quarters Estimate 1.503
FY Report Date 06 / 2026 Current Year's Estimate 4.915
Last Quarter’s Earnings 0.825 Median PE on CY Estimate N/A
Year Ago Earnings 4.55 Next Fiscal Year Estimate 5.98
Median PE on Next FY Estimate N/A

Earnings Per Share

This Quarter Next Quarter This Fiscal Next Fiscal
# of Estimates 4 4 4 4
Mean Estimate 1.50 1.64 4.92 5.98
High Estimates 1.59 1.74 5.05 6.25
Low Estimate 1.38 1.55 4.80 5.70
Coefficient of Variance 6.99 4.84 2.08 4.53

Analysts Recommendations

Current 1 Month Ago 3 Months Ago
BUY 3 3 3
OVERWEIGHT 0 0 0
HOLD 1 1 1
UNDERWEIGHT 0 0 0
SELL 0 0 0
MEAN Overweight Overweight Overweight

Insider Actions for Ingevity Corp. - NGVT

Date Name Shares Transaction Value
Mar 5, 2026 Mary Dean Hall EVP, Chief Financial Officer 37,427 Payment of exercise price or tax liability by delivering/withholding secs incident to the receipt/exercise/vesting pursuant to Rule 16b-3 Non-derivative transaction at $71.64 per share 2,681,270.28
Mar 5, 2026 Clarence Reid Clontz SVP, Operations 8,980 Payment of exercise price or tax liability by delivering/withholding secs incident to the receipt/exercise/vesting pursuant to Rule 16b-3 Non-derivative transaction at $71.64 per share 643,327.20
Mar 5, 2026 Ryan C. Fisher SVP, Gen. Counsel & Secretary 19,182 Payment of exercise price or tax liability by delivering/withholding secs incident to the receipt/exercise/vesting pursuant to Rule 16b-3 Non-derivative transaction at $71.64 per share 1,374,198.48
Mar 5, 2026 Ryan C. Fisher SVP, Gen. Counsel & Secretary 19,285 Payment of exercise price or tax liability by delivering/withholding secs incident to the receipt/exercise/vesting pursuant to Rule 16b-3 Non-derivative transaction at $71.64 per share 1,381,577.40
Mar 5, 2026 Ryan C. Fisher SVP, Gen. Counsel & Secretary 19,640 Payment of exercise price or tax liability by delivering/withholding secs incident to the receipt/exercise/vesting pursuant to Rule 16b-3 Non-derivative transaction at $71.64 per share 1,407,009.60
Mar 5, 2026 Ryan C. Fisher SVP, Gen. Counsel & Secretary 19,835 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00
Mar 5, 2026 Phillip J. Platt SVP, Finance & CAO 29,949 Payment of exercise price or tax liability by delivering/withholding secs incident to the receipt/exercise/vesting pursuant to Rule 16b-3 Non-derivative transaction at $71.64 per share 2,145,546.36
Mar 5, 2026 Phillip J. Platt SVP, Finance & CAO 30,289 Payment of exercise price or tax liability by delivering/withholding secs incident to the receipt/exercise/vesting pursuant to Rule 16b-3 Non-derivative transaction at $71.64 per share 2,169,903.96
Mar 5, 2026 Phillip J. Platt SVP, Finance & CAO 30,388 Payment of exercise price or tax liability by delivering/withholding secs incident to the receipt/exercise/vesting pursuant to Rule 16b-3 Non-derivative transaction at $71.64 per share 2,176,996.32
Mar 5, 2026 Phillip J. Platt SVP, Finance & CAO 30,795 Payment of exercise price or tax liability by delivering/withholding secs incident to the receipt/exercise/vesting pursuant to Rule 16b-3 Non-derivative transaction at $71.64 per share 2,206,153.80
Mar 5, 2026 Phillip J. Platt SVP, Finance & CAO 31,019 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00
Mar 5, 2026 David H. Li President & CEO; Director 156,890 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00
Mar 5, 2026 Mary Dean Hall EVP, Chief Financial Officer 39,106 Payment of exercise price or tax liability by delivering/withholding secs incident to the receipt/exercise/vesting pursuant to Rule 16b-3 Non-derivative transaction at $71.64 per share 2,801,553.84
Mar 5, 2026 Mary Dean Hall EVP, Chief Financial Officer 39,665 Payment of exercise price or tax liability by delivering/withholding secs incident to the receipt/exercise/vesting pursuant to Rule 16b-3 Non-derivative transaction at $71.64 per share 2,841,600.60
Mar 5, 2026 Mary Dean Hall EVP, Chief Financial Officer 41,028 Payment of exercise price or tax liability by delivering/withholding secs incident to the receipt/exercise/vesting pursuant to Rule 16b-3 Non-derivative transaction at $71.64 per share 2,939,245.92
Mar 5, 2026 Richard A. White SVP and Pres, Perf Chemicals 20,080 Payment of exercise price or tax liability by delivering/withholding secs incident to the receipt/exercise/vesting pursuant to Rule 16b-3 Non-derivative transaction at $71.64 per share 1,438,531.20
Mar 5, 2026 Richard A. White SVP and Pres, Perf Chemicals 20,835 Payment of exercise price or tax liability by delivering/withholding secs incident to the receipt/exercise/vesting pursuant to Rule 16b-3 Non-derivative transaction at $71.64 per share 1,492,619.40
Mar 5, 2026 Richard A. White SVP and Pres, Perf Chemicals 21,052 Payment of exercise price or tax liability by delivering/withholding secs incident to the receipt/exercise/vesting pursuant to Rule 16b-3 Non-derivative transaction at $71.64 per share 1,508,165.28
Mar 5, 2026 Richard A. White SVP and Pres, Perf Chemicals 21,669 Payment of exercise price or tax liability by delivering/withholding secs incident to the receipt/exercise/vesting pursuant to Rule 16b-3 Non-derivative transaction at $71.64 per share 1,552,367.16
Mar 5, 2026 Terrence M. Dyer SVP, Chief HR Officer 7,698 Payment of exercise price or tax liability by delivering/withholding secs incident to the receipt/exercise/vesting pursuant to Rule 16b-3 Non-derivative transaction at $71.64 per share 551,484.72

Ingevity Corp. in the News